Health

Lions Health: 2018 health and wellness winners

Lions Health: 2018 health and wellness winners

Here are the Lions Health winners in the health and wellness category.

Confusion expected in wake of 'Right to Try' bill's signing

Confusion expected in wake of 'Right to Try' bill's signing

It's still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.

Comms outreach efforts pass the test for Interpace

Comms outreach efforts pass the test for Interpace

A combination of traditional and modern comms tactics help molecular diagnostic testing company Interpace craft messages that resonate with all key audiences.

Five things for pharma marketers to know: Monday, June 4, 2018

Five things for pharma marketers to know: Monday, June 4, 2018

By

New study finds early-stage breast cancer may not need chemo; Merck's Keytruda succeeds in more studies; Athenahealth CEO faces allegations of inappropriate behavior

Transparency may have taken a back seat on this diversity drive

Transparency may have taken a back seat on this diversity drive

By

MM&M/Publicis Health's first Diversity Survey reveals some notable shifts to making the healthcare industry more inclusive, yet many agencies didn't feel like opening up about their diversity numbers.

Interview | Sam Cannizzaro, GSW, a Syneos Health company

Interview | Sam Cannizzaro, GSW, a Syneos Health company

By

Sam Cannizzaro, executive creative director at GSW, a Syneos Health company,discusses the agency's response to the rapid pace of change in healthcare marketing.

How drugmakers are facing the entrance of consumer giants into healthcare

How drugmakers are facing the entrance of consumer giants into healthcare

By

As deepening healthcare forays by tech and e-commerce giants ratchet up the pressure on pharma to become more consumer friendly, drugmakers are still defining their new role.

MM&M Hall of Femme 2018: The profiles

MM&M Hall of Femme 2018: The profiles

MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.

Alisa Lask, Galderma

Alisa Lask, Galderma

Alisa Lask is VP and GM, U.S. aesthetic business unit of Galderma, Nestlé Skin Health.

Johanna Skilling, Ogilvy CommonHealth Worldwide

Johanna Skilling, Ogilvy CommonHealth Worldwide

Johanna Skilling is head of planning of Ogilvy CommonHealth Worldwide.

Neera Chaudhary, Golin

Neera Chaudhary, Golin

Neera Chaudhary is global president of healthcare of Golin.

Elena Cant, Takeda

Elena Cant, Takeda

Elena Cant is VP, global head of vaccine commercial, Takeda Vaccine Business Unit of Takeda.

Meghan Rivera, Amag Pharmaceuticals

Meghan Rivera, Amag Pharmaceuticals

Meghan Rivera is VP, digital customer engagement of Amag Pharmaceuticals.

Becky Chidester,  Wunderman Health

Becky Chidester, Wunderman Health

Becky Chidester is CEO of Wunderman Health.

Wendy Blackburn, Intouch Solutions

Wendy Blackburn, Intouch Solutions

Wendy Blackburn is EVP, marketing and communications of Intouch Solutions.

Kathy Delaney, Publicis Health

Kathy Delaney, Publicis Health

Kathy Delaney is chief creative officer of Publicis Health.

Deborah Profit, Ostuka

Deborah Profit, Ostuka

Deborah Profit is VP, Otsuka Information Technology at Ostuka.

Wendy Lund, GCI Health

Wendy Lund, GCI Health

Wendy Lund is CEO of GCI Health.

Vanessa Thirion-Cullity, Novartis Oncology

Vanessa Thirion-Cullity, Novartis Oncology

Vanessa Thirion-Cullity is executive director, U.S. NET of Novartis Oncology.

Meet the 2018 Women to Watch Honorees

Meet the 2018 Women to Watch Honorees

MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.

Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk

Former FDA commissioner Califf to pharma: opening up on health data requires overcoming risk

By

Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.

Whither the pharma Grand Prix? Questions abound in run-up to Cannes health fest

Whither the pharma Grand Prix? Questions abound in run-up to Cannes health fest

Whether jurors will award a pharma Grand Prix, and whether US pharma will show up, are two open questions in the run-up to Lions Health.

'Not a good day for Novartis': how the Novartis-Cohen crisis unfolded

'Not a good day for Novartis': how the Novartis-Cohen crisis unfolded

By

Here's a recap of the Novartis-Michael Cohen crisis, which unfolded this week, including how the drugmaker has responded to scrutiny over its $1.2 million contract with Cohen's firm.

Evidence-based patient access programs

Evidence-based patient access programs

By

At the Asembia Specialty Pharma summit, speakers described a healthcare ecosystem in which specialty products will represent nearly half of all drug spending.

Interview | Paul LeVine, TrialCard

Interview | Paul LeVine, TrialCard

By

Paul LeVine, VP, Analytic Services for TrialCard, describes proven strategies that prevent patient adherence fall off, driven by evidenced-based design and patient engagement programs.

Trust in health sector takes a hit in major markets, Edelman research finds

Trust in health sector takes a hit in major markets, Edelman research finds

By

The healthcare sector has suffered a dip in public trust in major markets including France, India and the US, but Britons remain among the more trusting globally, according to the Edelman Health Trust Barometer.

Interview | Gary Scheiner, GHG

Interview | Gary Scheiner, GHG

By

Gary Scheiner, EVP and chief creative officer at GHG, discusses the inherent tension in day-to-day marketing for healthcare brands.

Merck's Gerberding, Publicis Health's Colucci call for courage in tackling gender parity

Merck's Gerberding, Publicis Health's Colucci call for courage in tackling gender parity

By

Both leaders were honored at Healthcare Businesswomen's Association 2018 Woman of the Year event in New York.

How pharma and healthcare shifted strategies post-blockbuster drug success

How pharma and healthcare shifted strategies post-blockbuster drug success

Remedy Health Media's Mike Collins discusses ways pharma and healthcare companies have shifted their strategies in the years after the success of blockbuster drugs.

Drugs' value to patients eclipsed by price tags

Drugs' value to patients eclipsed by price tags

Like other sectors, pharma is experiencing upheavals no one predicted, and as a result, drugs are being reviled for their price tags, rather than praised for their value.